Chastain Daniel B, Zhang Qian, Chen Xianyan, Young Henry N, Franco-Paredes Carlos, Tuells Jose, Thompson George R, Henao-Martínez Andrés F
Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, 1000 Jefferson Street, Albany, GA 31701, USA.
Department of Statistics, University of Georgia Franklin College of Arts and Sciences, Athens, GA, USA.
Ther Adv Infect Dis. 2024 Apr 18;11:20499361241244967. doi: 10.1177/20499361241244967. eCollection 2024 Jan-Dec.
Emerging risk factors highlight the need for an updated understanding of cryptococcosis in the United States.
Describe the epidemiological trends and clinical outcomes of cryptococcosis in three patient groups: people with HIV (PWH), non-HIV-infected and non-transplant (NHNT) patients, and patients with a history of solid organ transplantation.
We utilized data from the Merative Medicaid Database to identify individuals aged 18 and above with cryptococcosis based on the International Classification of Diseases, Tenth Revision diagnosis codes from January 2017 to December 2019. Patients were stratified into PWH, NHNT patients, and transplant recipients according to Infectious Diseases Society of America guidelines. Baseline characteristics, types of cryptococcosis, hospitalization details, and in-hospital mortality rates were compared across groups.
Among 703 patients, 59.7% were PWH, 35.6% were NHNT, and 4.7% were transplant recipients. PWH were more likely to be younger, male, identify as Black, and have fewer comorbidities than patients in the NHNT and transplant groups. Notably, 24% of NHNT patients lacked comorbidities. Central nervous system, pulmonary, and disseminated cryptococcosis were most common overall (60%, 14%, and 11%, respectively). The incidence of cryptococcosis fluctuated throughout the study period. PWH accounted for over 50% of cases from June 2017 to June 2019, but this proportion decreased to 47% from July to December 2019. Among the 52% of patients requiring hospitalization, 61% were PWH and 35% were NHNT patients. PWH had longer hospital stays. In-hospital mortality at 90 days was significantly higher in NHNT patients (22%) compared to PWH (7%) and transplant recipients (0%). One-year mortality remained lowest among PWH (8%) compared to NHNT patients (22%) and transplant recipients (13%).
In this study, most cases of cryptococcosis were PWH. Interestingly, while the incidence remained relatively stable in PWH, it slightly increased in those without HIV by the end of the study period. Mortality was highest in NHNT patients.
新出现的风险因素凸显了在美国对隐球菌病进行更新认识的必要性。
描述三类患者群体中隐球菌病的流行病学趋势和临床结局:艾滋病毒感染者(PWH)、未感染艾滋病毒且未接受移植者(NHNT)以及有实体器官移植史的患者。
我们利用默克医疗补助数据库的数据,根据2017年1月至2019年12月的国际疾病分类第十版诊断编码,识别18岁及以上患有隐球菌病的个体。根据美国传染病学会指南,将患者分为PWH、NHNT患者和移植受者。比较各组的基线特征、隐球菌病类型、住院细节和住院死亡率。
在703例患者中,59.7%为PWH,35.6%为NHNT,4.7%为移植受者。与NHNT组和移植组患者相比,PWH更可能年龄较小、为男性、自我认定为黑人且合并症较少。值得注意的是,24%的NHNT患者没有合并症。中枢神经系统、肺部和播散性隐球菌病总体上最为常见(分别为60%、14%和11%)。在整个研究期间,隐球菌病的发病率有所波动。2017年6月至2019年6月,PWH占病例的50%以上,但这一比例在2019年7月至12月降至47%。在需要住院治疗的52%的患者中,61%为PWH,35%为NHNT患者。PWH的住院时间更长。NHNT患者90天的住院死亡率(22%)显著高于PWH(7%)和移植受者(0%)。与NHNT患者(22%)和移植受者(13%)相比,PWH的一年死亡率仍然最低(8%)。
在本研究中,大多数隐球菌病病例为PWH。有趣的是,虽然PWH的发病率保持相对稳定,但在研究期结束时,未感染艾滋病毒者的发病率略有上升。NHNT患者的死亡率最高。